Intravenous Alteplase in CADASIL
نویسندگان
چکیده
منابع مشابه
Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone.
BACKGROUND AND PURPOSE Thrombectomy, primarily with stent retrievers with or without adjunctive aspiration, provided clinical benefit across multiple prospective randomized trials. Whether this benefit is exclusive to stent retrievers is unclear. METHODS THERAPY (The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stro...
متن کاملAdministering Intravenous Alteplase (Tissue Plasminogen Activator [tPA])
Step 1: Eligibility-The eligibility criteria for patients with acute ischemic stroke within 3 hours of symptom onset include: • An adult (> 18 years of age) • Exclusion of intrancranial hemorrhage by an imaging technique sensitive for the presence of hemorrhage • Arrives at the emergency department in time to be treated within 3 hours of symptom onset • The recommended dose of IV tPA is 0.9 mg/...
متن کاملLow-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
BACKGROUND Thrombolytic therapy for acute ischemic stroke with a lower-than-standard dose of intravenous alteplase may improve recovery along with a reduced risk of intracerebral hemorrhage. METHODS Using a 2-by-2 quasi-factorial open-label design, we randomly assigned 3310 patients who were eligible for thrombolytic therapy (median age, 67 years; 63% Asian) to low-dose intravenous alteplase ...
متن کاملThrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice
Background and Purpose—In Japan, alteplase at 0.6 mg/kg was approved in October 2005 for use within 3 hours of stroke onset by the Ministry of Health, Labor and Welfare (MHLW). The aim of the Japan post-Marketing Alteplase Registration Study (J-MARS), which was requested by MHLW at the time of approval, was to assess the safety and efficacy of 0.6 mg/kg alteplase in routine clinical practice fo...
متن کاملIntravenous alteplase for stroke in those older than 80 years old.
BACKGROUND AND PURPOSE Risks and benefits of intravenous thrombolysis for patients with stroke > 80 years of age are unclear. We examined outcomes and symptomatic intracerebral hemorrhage rates in ≤ 80- and > 80-year-old patients in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register. METHODS We compared mortality and independence (modified Rankin Scale 0...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Graduate medical education research journal
سال: 2023
ISSN: ['2578-6091', '2578-6105']
DOI: https://doi.org/10.32873/unmc.dc.gmerj.5.1.070